• Key member of leadership team identifying and partnering with innovative health systems, medical groups, advocacy organizations, KOLs, Medicaid programs, high value consultants and vendors
• Developed innovative value-based contracting frameworks and proposals
• Led a dynamic team of payer and employer contracting & relations professionals; signed multiple contracts within 5 months of product launch

• Successfully obtained dedicated AMA PLA CPT code and CMS fee schedule reimbursement
• Established in-house billing & patient access functions, facilitating claims submission, appeals, dedicated patient support and test payment

• Devised and executed commercialization market access strategy including pricing, reimbursement (coverage, coding, payment) payer, and employer access strategies (aligned with sales, marketing, commercial operations) for a novel proteomic blood test for early preterm birth risk stratification;

Boutique health economics and market access consultancy helping biotech companies bridge the gaps between commercialization, Health Economics Outcomes Research (HEOR) and Market Access; with focus on customized, evidence-based market access pathways, value-driven payment modalities, medical policy implementation, contracting and strategic partnering opportunities

• Led efforts to develop and communicate the GPS Cancer Test evidence-based value proposition to facilitate market adoption
• Drove cross functional efforts to devise/implement HEOR-based initiatives to illustrate impact of testing on physician behavior, patient outcomes, quality of life and cost; ultimately driving long term, value-based contracting as well as data collection/analysis/publication opportunities
• Worked closely with payer, employer and field sales teams to devise and facilitate

Manufacturer of GPS Cancer™, a novel molecular test integrating quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing, of both normal and cancer tissue; provides oncologists with the most comprehensive molecular profile of a patient's cancer to inform personalized treatment strategies.
• Successfully led commercial operations efforts across Nant ecosystem of companies
• Met GPS Cancer commercial soft launch objectives

Manufacturer of the OncoPlexDx test, a novel solid organ tumor protein expression test allowing for individualized treatment strategies by providing a therapeutically-relevant multi biomarker snapshot generated by absolute quantitation of multiple proteins as well as multi-gene mutation analysis from the same tumor tissue; OncoPlex purchased in full by NantOmics, May 2015
• Responsible for developing payer access, reimbursement, health economics strategies

• Worked with professional society KOLs and CMS to obtain CPT code with favorable reimbursement for novel dx test, InflammaDry, for Dry Eye Disease (DED)
• Developed and collaborated on development of managed care health economic budget impact calculators and subsequent supporting publications in Journal of Managed Care Medicine (JMCM)
• Obtained VSP coverage and payment for InflammaDry- a critical payer for practicing optometrists
• Managed 3rd party customer reimbursement support team.

• Drove comprehensive, novel diagnostic test reimbursement, health economics and managed care payer strategies
• Developed/published managed care budget impact model
• Hired and led team of two Dir, Payer Contracting & Sr. Mgr, Health Econ\ & Reimbursement that drove contracts with several health plans as well positive medical policy assessments by Blue TEC, Anthem and regional and local payers within 9 months of product launch
• Illumina purchased Verinata Health for ~$450M,2012/13

• Leveled “playing field” for flu test reimbursement
• Discovered that Quidel competitors were able to submit 2 CPT codes for flu testing as opposed to 1 for Quidel
• Submitted 2 AMA CPT code applications leading to updated coding guidelines, enabling submission 2 CPT codes for Quidel's rapid flu test
• Improved reimbursement, facilitated sales efforts, helped double revenues in 2 years
• Established new managed care presence in CA